ArticleAdvanced healthcare materials2026
Dual-Modal Phototherapeutic Nanoagents Eradicating Drug-Resistant Bacteria via Multi-Pathway of Membrane Disruption, Oxidative Damage, and Energy Metabolism Interference.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Faced with the growing challenge of antimicrobial resistance, developing non-antibiotic therapies is imperative. Photodynamic and photothermal therapy (PDT/PTT) are promising due to their minimal side effects and low risk of resistance. However, their efficacy is limited by inadequate reactive oxygen species (ROS) generation, finite photothermal conversion efficiency (PCE), bacterial antioxidant systems, biofilm barriers, and the constraints of single-modality treatments. To overcome these bottlenecks, this study innovatively co-assembled the phototherapeutic molecule Y6 with allicin (A) into the Y6A nanoplatform to achieve multi-mechanism antibacterial activity. Leveraging Y6's strong intramolecular charge transfer (ICT), extended π-conjugated backbone, and twisted long alkyl chain, Y6A simultaneously achieves efficient ROS generation and 55.2% PCE. Thus, Y6A eradicated up to 99.9% of Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa). This high efficacy is attributed to a synergistic antimicrobial strategy that couples structural disruption and oxidative damage via bimodal phototherapy with allicin-mediated suppression of biofilm formation and energy metabolism. In an MRSA-infected wound model, irradiated Y6A accelerated healing by 90%, modulating inflammation and promoting collagen deposition. This work not only confirms the exceptional PDT/PTT efficacy of Y6A against drug-resistant bacteria but also provides innovative concepts and experimental evidence for the development of synergistic phototherapeutic antibacterial materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.